CA2420045A1 - Ligands de recepteurs de la melanocortine - Google Patents

Ligands de recepteurs de la melanocortine Download PDF

Info

Publication number
CA2420045A1
CA2420045A1 CA002420045A CA2420045A CA2420045A1 CA 2420045 A1 CA2420045 A1 CA 2420045A1 CA 002420045 A CA002420045 A CA 002420045A CA 2420045 A CA2420045 A CA 2420045A CA 2420045 A1 CA2420045 A1 CA 2420045A1
Authority
CA
Canada
Prior art keywords
hydrogen
alkyl
ring
mmol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002420045A
Other languages
English (en)
Inventor
Frank Hallock Ebetino
Adam W. Mazur
Jeffrey Charles Hayes
Feng Wang
Mark Gregory Solinsky
Anny-Odile Colson
Qishen Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2420045A1 publication Critical patent/CA2420045A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)

Abstract

L'invention concerne des ligands de récepteurs MC-4 et/ou MC-3, ces ligands présentant une structure représentée par la formule (I), dans laquelle R?2¿, R?4¿, R?4'¿, R?5¿, R?6¿, R?6'¿, R?7¿, R?8¿, R?8'¿, R?9¿, R?9'¿, R?10¿, Ar, Z?1¿, Z?2¿, Z?3¿, X, B, D, p, q, r et s sont tels que décrits dans la spécification et les revendications ; et des isomères optiques, des diastéréomères ou des énantiomères de ces composés ; des sels pharmaceutiquement acceptables, des hydrates, ainsi que des esters, des amides ou des imides biohydrolysables de ceux-ci. L'invention concerne aussi des compositions pharmaceutiques contenant les ligands représentés par la formule (I), ainsi que des procédés, décrits dans la partie descriptions détaillées de la spécification, visant à traiter des maladies dépendant des récepteurs MC-4/MC-3.
CA002420045A 2000-09-27 2001-09-26 Ligands de recepteurs de la melanocortine Abandoned CA2420045A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23585800P 2000-09-27 2000-09-27
US60/235,858 2000-09-27
PCT/US2001/030051 WO2002026774A2 (fr) 2000-09-27 2001-09-26 Ligands de recepteurs de la melanocortine

Publications (1)

Publication Number Publication Date
CA2420045A1 true CA2420045A1 (fr) 2002-04-04

Family

ID=22887187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002420045A Abandoned CA2420045A1 (fr) 2000-09-27 2001-09-26 Ligands de recepteurs de la melanocortine

Country Status (19)

Country Link
EP (1) EP1409540A2 (fr)
JP (1) JP2004509974A (fr)
KR (1) KR100519204B1 (fr)
CN (1) CN1571796A (fr)
AR (1) AR030806A1 (fr)
AU (2) AU9631301A (fr)
BR (1) BR0114257A (fr)
CA (1) CA2420045A1 (fr)
CZ (1) CZ2003788A3 (fr)
HU (1) HUP0303085A2 (fr)
IL (1) IL154437A0 (fr)
MX (1) MXPA03002691A (fr)
NO (1) NO20031287D0 (fr)
NZ (1) NZ524190A (fr)
PE (1) PE20020447A1 (fr)
PL (1) PL362003A1 (fr)
RU (1) RU2246501C2 (fr)
WO (1) WO2002026774A2 (fr)
ZA (1) ZA200301561B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
ATE550041T1 (de) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag Transglutaminase-vermittelte konjugation von peptiden
RU2309144C2 (ru) * 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
MX2008012991A (es) 2006-04-07 2008-10-17 Procter & Gamble Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos.
RU2303597C1 (ru) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008107362A2 (fr) * 2007-03-07 2008-09-12 Novo Nordisk Health Care Ag Nouveaux inhibiteurs du facteur de coagulation sanguine
MX2010013436A (es) 2008-06-09 2011-06-21 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de disfuncion sexual.
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
MX2011013117A (es) 2009-06-08 2012-05-23 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina.
WO2010144341A2 (fr) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Peptides spécifiques des récepteurs aux mélanocortines à pont lactame
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
KR101426125B1 (ko) 2009-07-06 2014-08-06 에르피오 세러퓨틱스 인코포레이티드 암 세포의 전이 예방을 위한 화합물, 조성물 및 방법
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
RU2012125033A (ru) * 2009-11-16 2014-01-20 Ипсен Фарма С.А.С. СПОСОБ СИНТЕЗА Ас-Arg-ЦИКЛО(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
EP2504351A4 (fr) 2009-11-23 2013-10-30 Palatin Technologies Inc Peptides linéaires spécifiques du récepteur de la mélanocortine-1
CN102725305B (zh) 2009-11-23 2016-08-24 帕拉丁科技公司 黑皮质素-1受体特异性环肽
US10347423B2 (en) 2014-05-12 2019-07-09 Capacitor Sciences Incorporated Solid multilayer structure as semiproduct for meta-capacitor
RU2016143558A (ru) 2014-05-12 2018-06-13 Кэпэситор Сайенсиз Инкорпорейтед Устройство для хранения энергии и способ его изготовления
US10340082B2 (en) 2015-05-12 2019-07-02 Capacitor Sciences Incorporated Capacitor and method of production thereof
AU2015343211A1 (en) 2014-11-04 2017-04-27 Capacitor Sciences Incorporated Energy storage devices and methods of production thereof
CA2977776A1 (fr) 2015-02-26 2016-09-01 Capacitor Sciences Incorporated Condensateur autoregenerateur et ses procedes de production
US9932358B2 (en) * 2015-05-21 2018-04-03 Capacitor Science Incorporated Energy storage molecular material, crystal dielectric layer and capacitor
US9941051B2 (en) 2015-06-26 2018-04-10 Capactor Sciences Incorporated Coiled capacitor
US10026553B2 (en) 2015-10-21 2018-07-17 Capacitor Sciences Incorporated Organic compound, crystal dielectric layer and capacitor
US10305295B2 (en) 2016-02-12 2019-05-28 Capacitor Sciences Incorporated Energy storage cell, capacitive energy storage module, and capacitive energy storage system
US10153087B2 (en) 2016-04-04 2018-12-11 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US9978517B2 (en) 2016-04-04 2018-05-22 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US10395841B2 (en) 2016-12-02 2019-08-27 Capacitor Sciences Incorporated Multilayered electrode and film energy storage device
CN106966927B (zh) * 2017-04-13 2018-10-09 菲立化学工程（上海）有限公司 一种抗艾滋病药物中间体重氮酮与氯酮的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021571A1 (fr) * 1997-10-27 1999-05-06 Trega Biosciences, Inc. Ligands de recepteurs de melanocortine et procedes d'utilisation de ces ligands
PT1165613E (pt) * 1999-03-29 2008-07-29 Procter & Gamble Ligantes do receptor de melanocortina
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction

Also Published As

Publication number Publication date
PL362003A1 (en) 2004-10-18
NO20031287L (no) 2003-03-20
IL154437A0 (en) 2003-09-17
AU2001296313B2 (en) 2005-06-02
AU9631301A (en) 2002-04-08
HUP0303085A2 (hu) 2003-12-29
ZA200301561B (en) 2004-03-10
BR0114257A (pt) 2003-07-01
RU2246501C2 (ru) 2005-02-20
NZ524190A (en) 2004-09-24
NO20031287D0 (no) 2003-03-20
WO2002026774A3 (fr) 2003-03-27
PE20020447A1 (es) 2002-07-02
CZ2003788A3 (cs) 2003-08-13
CN1571796A (zh) 2005-01-26
KR100519204B1 (ko) 2005-10-06
MXPA03002691A (es) 2003-06-06
KR20030061814A (ko) 2003-07-22
WO2002026774A2 (fr) 2002-04-04
AR030806A1 (es) 2003-09-03
JP2004509974A (ja) 2004-04-02
EP1409540A2 (fr) 2004-04-21

Similar Documents

Publication Publication Date Title
CA2420045A1 (fr) Ligands de recepteurs de la melanocortine
AU2001296313A1 (en) Melanocortin receptor ligands
CA2368431C (fr) Ligands du recepteur de melanocortine
US7045591B2 (en) Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity
AU741216B2 (en) Phenethylamine derivatives
AU672077B2 (en) Opioid peptides
SK13222003A3 (sk) Ligandy melanokortínového receptora
CA2809803A1 (fr) Ligands de melanocortine stabilises
IE921321A1 (en) Ó-substituted polypeptides having therapeutic activity
CA1249100A (fr) Derives peptidiques, leur procede de preparation et les compositions les contenant
WO1993000359A1 (fr) Peptides modifies pouvant etre transportes vers le systeme nerveux central
US20060128613A1 (en) Melanocortin receptor ligands
Palkeeva et al. Fragments of the galanin peptide and their synthetic analogues with the cardioprotective effect
JP2000044595A (ja) フェネチルアミン誘導体
JPS62501212A (ja) サブスタンスｐ及びそのフラグメントの誘導体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued